GLP-1 drug interactions: what each label says
The short answer
Ozempic drug interactions and those of other GLP-1 medicines fall into three groups on the labels. Insulin and sulfonylureas raise the risk of low blood sugar. Slower stomach emptying can change how other oral medicines are absorbed. And if you take birth control pills, the Zepbound and Mounjaro labels advise backup contraception for 4 weeks after starting and after each dose increase.
Key takeaways
- Give your prescriber and pharmacist a complete list of what you take, including non-prescription medicines.
- Insulin or a sulfonylurea with a GLP-1 raises the risk of low blood sugar. Any dose change is your prescriber's decision.
- If you use birth control pills with Zepbound, Mounjaro or Foundayo, the labels advise backup after starting and each dose increase.
- With Rybelsus, Ozempic tablets or Wegovy tablets, wait at least 30 minutes before other oral medicines.
- The labels say taking two medicines of this class together isn't recommended on Zepbound, Wegovy, Saxenda or Foundayo.
GLP-1 labels list few named drug interactions, but the ones they do list apply to medicines many people take: insulin, sulfonylureas, birth control pills, warfarin, levothyroxine and statins. This page sets out what each label says.
It doesn’t replace an interaction check. Give your prescriber and pharmacist a complete list of what you take, including non-prescription medicines, and let them make any changes.
Insulin and sulfonylureas: low blood sugar
This is the interaction every label addresses. GLP-1 medicines lower blood glucose (blood sugar). Combining one with insulin or an insulin secretagogue, a medicine that makes the body release more insulin, such as a sulfonylurea, increases the risk of hypoglycemia, or low blood sugar.
The standard label instruction is for the prescriber: when starting the GLP-1, consider reducing the dose of the insulin or sulfonylurea. That wording appears on the Zepbound, Mounjaro, Foundayo, Trulicity, Ozempic and Rybelsus labels. The Saxenda label says the risk may be lowered by a reduction in the dose of the sulfonylurea or insulin. The Wegovy label says the risk of hypoglycemia is increased with insulin or sulfonylureas, and adds that the addition of Wegovy in patients treated with insulin has not been evaluated.
The labels report how often low blood sugar occurred with a sulfonylurea in their trials. These figures come from separate trials with different definitions and lengths. So they describe each drug, and you can’t use them to rank the drugs:
- Zepbound: in its trial in people with type 2 diabetes, hypoglycemia occurred in 10.3% of patients also taking a sulfonylurea and 2.1% of those not taking one.
- Mounjaro: in a trial of up to 104 weeks, hypoglycemia (glucose below 54 mg/dL) occurred in 13.8%, 9.9% and 12.8% of patients on 5 mg, 10 mg and 15 mg with a sulfonylurea.
- Foundayo: in its second trial, hypoglycemia was reported by 7% of patients taking it with a sulfonylurea, compared with 0.5% of those not taking a sulfonylurea.
- Trulicity: in a 78-week trial, hypoglycemia (glucose below 54 mg/dL) occurred in 20% and 21% of patients on 0.75 mg and 1.5 mg with a sulfonylurea.
- Ozempic: documented symptomatic hypoglycemia occurred in 17.3% and 24.4% of patients on 0.5 mg and 1 mg with a sulfonylurea.
- Saxenda: among adults with type 2 diabetes taking a sulfonylurea, glucose below 54 mg/dL occurred in 28.2% on Saxenda and 12.7% on placebo, an inactive treatment.
If you take insulin, the Ozempic, Mounjaro and Trulicity labels also cover the mechanics: separate injections, never mixed, and not next to each other even when given in the same body region.
Other oral medicines: slower stomach emptying
GLP-1 medicines delay gastric (stomach) emptying, which means anything you swallow may reach the intestine later than it otherwise would. The label wording is cautious:
- Zepbound and Mounjaro: the potential to affect the absorption of other oral medications taken at the same time. Caution should be exercised.
- Foundayo, Ozempic and Saxenda: the potential to affect the absorption of other oral medications taken at the same time.
- Trulicity: the potential to reduce the rate of absorption of oral medications. The label adds a specific instruction: monitor drug levels of oral medications with a narrow therapeutic index, meaning a small change in level can matter, such as warfarin, when they’re taken with Trulicity.
- Wegovy: monitor the effects of oral medications taken with Wegovy.
Levothyroxine. This thyroid medicine is the one measured example in our records. In a drug interaction study with semaglutide tablets, levothyroxine exposure was increased 33%. That finding is on the Rybelsus and Ozempic tablets label and is cited on the Wegovy label. The labels don’t tell patients to change a thyroid dose. If you take levothyroxine, tell your prescriber so that monitoring can be arranged.
Birth control pills
The stomach-emptying effect is the reason three labels single out oral contraceptives.
Zepbound and Mounjaro. Use may reduce how well oral hormonal contraceptives work. The delay in stomach emptying is largest after the first dose and shrinks over time. The labels advise switching to a non-oral contraceptive method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase.
Foundayo. The label advises switching to a non-oral method or adding a barrier method for 30 days after starting and for 30 days after each dose increase. It notes that hormonal contraceptives that aren’t taken by mouth should not be affected.
Since these medicines move up through several doses, the backup period comes round again with each step. The titration schedule tool shows the dates of each increase.
The pregnancy and breastfeeding page covers the rest of the labels’ reproductive guidance.
Foundayo: interactions the injectables do not have
Foundayo (orforglipron) is a once-daily tablet, and its label lists enzyme-based interactions. CYP3A4 is an enzyme the body uses to break down many drugs. An inhibitor slows it and an inducer speeds it up.
- Strong CYP3A4 inhibitors. The maximum Foundayo dosage is 9 mg once daily when it’s used with a strong CYP3A4 inhibitor.
- Strong CYP3A4 inhibitors that also inhibit OATP1B. Avoid.
- Strong CYP3A4 inducers. Avoid.
- Simvastatin. Do not exceed simvastatin 20 mg once daily when it’s used with Foundayo.
Which specific medicines belong to the inhibitor and inducer groups is a question for your pharmacist, who can check your list against those categories. There’s more on the medicine on the Foundayo page.
The semaglutide tablets: timing with other medicines
Rybelsus, Ozempic tablets and Wegovy tablets have a rule that works as an interaction rule for everything else you swallow. The tablet is taken in the morning on an empty stomach with up to 4 ounces of water. Then you wait at least 30 minutes before eating food, drinking beverages or taking other oral medications.
So other morning pills come after the 30-minute wait, not with the tablet.
Other GLP-1 medicines
The labels don’t recommend taking two medicines of this class together. Zepbound is not recommended with other tirzepatide-containing products or any GLP-1 receptor agonist. Wegovy is not recommended with other semaglutide-containing products or any other GLP-1 receptor agonist. Saxenda is not recommended with other liraglutide-containing products or any other GLP-1 receptor agonist, and Foundayo is not recommended with another GLP-1 receptor agonist. This matters most during a switch, when one medicine stops before the next begins. The switching planner shows what the labels say about timing.
The wider picture, including who should not take these medicines at all, is in the GLP-1 safety guide and on the page about contraindications.
Frequently asked questions
Does Zepbound interfere with birth control?
It may. The Zepbound label says it may reduce how well oral hormonal contraceptives work, because it delays stomach emptying. It advises switching to a non-oral contraceptive method, or adding a barrier method such as condoms, for 4 weeks after starting Zepbound and for 4 weeks after each dose increase. The Mounjaro label gives the same advice.
Can you take Ozempic with insulin?
The label plans for it. It says that when starting Ozempic, the prescriber should consider reducing the dose of a sulfonylurea or insulin you take with it, to reduce the risk of hypoglycemia (low blood sugar). The two are given as separate injections and never mixed. Any change to your insulin dose is your prescriber's decision.
Does Ozempic interact with levothyroxine?
The label finding is for the semaglutide tablets: levothyroxine exposure rose 33% when it was given with semaglutide tablets in a drug interaction study. The Wegovy label cites the same study and says to monitor the effects of oral medications taken with Wegovy. If you take levothyroxine, tell your prescriber.
What medicines should not be taken with Foundayo?
The Foundayo label says to avoid strong CYP3A4 inducers and strong CYP3A4 inhibitors that also inhibit OATP1B. With other strong CYP3A4 inhibitors, the maximum Foundayo dosage is 9 mg once daily. Simvastatin should not exceed 20 mg once daily. Your pharmacist can tell you which of your medicines fall into those groups.
Can I take other pills at the same time as Rybelsus or the Wegovy pill?
Not at the same moment. The labels for Rybelsus, Ozempic tablets and Wegovy tablets say to wait at least 30 minutes after taking the tablet before eating food, drinking beverages or taking other oral medications. The tablet itself is taken on an empty stomach in the morning with up to 4 ounces of water.
Sources (36)
- 1.FDA label (DailyMed): Zepbound prescribing information, section 7.1
“ZEPBOUND lowers blood glucose. When initiating ZEPBOUND, consider reducing the dose of concomitantly administered insulin or insulin secretagogues (e.g., sulfonylureas) to reduce the risk of hypoglycemia [see Warnings and Precautions (5.7)].”
- 2.FDA label (DailyMed): Zepbound prescribing information, section 5.7
“In this trial, patients taking ZEPBOUND in combination with an insulin secretagogue (e.g., sulfonylurea) had increased risk of hypoglycemia (10.3%) compared to ZEPBOUND-treated patients not taking a sulfonylurea (2.1%).”
- 3.FDA label (DailyMed): Zepbound prescribing information, section 7.2
“ZEPBOUND delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications. Caution should be exercised when oral medications are concomitantly administered with ZEPBOUND.”
- 4.FDA label (DailyMed): Zepbound prescribing information, section 8.3
“Use of ZEPBOUND may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation [see Drug Interactions (7.2) and Clinical Pharmacology (12.2, 12.3)].”
- 5.FDA label (DailyMed): Zepbound prescribing information, section 1
“ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
- 6.FDA label (DailyMed): Mounjaro prescribing information, section 7.1
“When initiating MOUNJARO, consider reducing the dose of concomitantly administered insulin secretagogues (e.g., sulfonylureas) or insulin to reduce the risk of hypoglycemia [see Warnings and Precautions (5.3)].”
- 7.FDA label (DailyMed): Mounjaro prescribing information, section 6.1
“In an adult clinical trial up to 104 weeks of treatment, when administered with a sulfonylurea, hypoglycemia (glucose level <54 mg/dL) occurred in 13.8%, 9.9%, and 12.8%, and severe hypoglycemia occurred in 0.5%, 0%, and 0.6% of patients treated with MOUNJARO 5 mg, 10 mg, and 15 mg, respectively.”
- 8.FDA label (DailyMed): Mounjaro prescribing information, section 7.2
“MOUNJARO delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications. Caution should be exercised when oral medications are concomitantly administered with MOUNJARO.”
- 9.FDA label (DailyMed): Mounjaro prescribing information, section 8.3
“Use of MOUNJARO may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with MOUNJARO [see Drug Interactions (7.2) and Clinical Pharmacology (12.2, 12.3)].”
- 10.FDA label (DailyMed): Mounjaro prescribing information, section 2.2
“When using MOUNJARO with insulin, administer as separate injections and never mix. It is acceptable to inject MOUNJARO and insulin in the same body region, but the injections should not be adjacent to each other.”
- 11.FDA label (DailyMed): Foundayo prescribing information, section 2.2
“The maximum dosage of FOUNDAYO is 9 mg once daily when used concomitantly with a strong CYP3A4 inhibitor [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].”
- 12.FDA label (DailyMed): Foundayo prescribing information, section 2.2
“Avoid strong CYP3A4 inhibitors that also inhibit OATP1B when taking FOUNDAYO. Avoid strong CYP3A4 inducers when taking FOUNDAYO.”
- 13.FDA label (DailyMed): Foundayo prescribing information, section 7.2, Table 3
“Do not exceed simvastatin 20 mg once daily when concomitantly used with FOUNDAYO.”
- 14.FDA label (DailyMed): Foundayo prescribing information, section 7.3
“FOUNDAYO delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications [see Clinical Pharmacology (12.3)].”
- 15.FDA label (DailyMed): Foundayo prescribing information, section 7.2, Table 3
“When initiating FOUNDAYO, consider reducing the dose of concomitantly administered insulin or insulin secretagogues (e.g., sulfonylureas) [see Warnings and Precautions (5.5)].”
- 16.FDA label (DailyMed): Foundayo prescribing information, section 5.5
“In Trial 2, 7% of patients treated with orforglipron once daily in combination with sulfonylurea reported hypoglycemia compared with 0.5% of patients not taking a sulfonylurea [see Adverse Reactions (6.1)].”
- 17.FDA label (DailyMed): Foundayo prescribing information, section 7.3
“Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 30 days after initiation with FOUNDAYO and for 30 days after each dose escalation. Hormonal contraceptives that are not administered orally should not be affected.”
- 18.FDA label (DailyMed): Foundayo prescribing information, section 1
“Concomitant use with another GLP-1 receptor agonist is not recommended.”
- 19.FDA label (DailyMed): Trulicity prescribing information, section 7.2
“When initiating TRULICITY, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia [see Warnings and Precautions (5.3) and Adverse Reactions (6.1)].”
- 20.FDA label (DailyMed): Trulicity prescribing information, section 6.1
“In a 78-week adult clinical trial, hypoglycemia (glucose level <54 mg/dL) occurred in 20% and 21% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with a sulfonylurea.”
- 21.FDA label (DailyMed): Trulicity prescribing information, section 7.1
“TRULICITY delays gastric emptying and thus has the potential to reduce the rate of absorption of concomitantly administered oral medications.”
- 22.FDA label (DailyMed): Trulicity prescribing information, section 7.1
“Monitor drug levels of oral medications with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with TRULICITY.”
- 23.FDA label (DailyMed): Wegovy prescribing information, section 7.1
“The risk of hypoglycemia is increased when WEGOVY is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylureas). The addition of WEGOVY in patients treated with insulin has not been evaluated.”
- 24.FDA label (DailyMed): Wegovy prescribing information, section 7.2
“In a drug interaction study with the semaglutide tablet, levothyroxine exposure was increased 33% (90% CI: 1.25-1.42). Monitor the effects of oral medications concomitantly administered with WEGOVY.”
- 25.FDA label (DailyMed): Wegovy prescribing information, section 1
“Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.”
- 26.FDA label (DailyMed): Wegovy prescribing information, section 2.1
“After taking a WEGOVY tablet, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications”
- 27.FDA label (DailyMed): Ozempic prescribing information, section 7.1
“When initiating OZEMPIC, consider reducing the dose of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia”
- 28.FDA label (DailyMed): Ozempic prescribing information, section 6.1
“Documented symptomatic hypoglycemia occurred in 17.3% and 24.4% of patients when OZEMPIC 0.5 mg and 1 mg, respectively, was coadministered with a sulfonylurea.”
- 29.FDA label (DailyMed): Ozempic prescribing information, section 7.2
“OZEMPIC causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications.”
- 30.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.1
“After taking RYBELSUS or OZEMPIC tablets, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications”
- 31.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 7.1
“When initiating RYBELSUS or OZEMPIC tablets, consider reducing the dosage of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia”
- 32.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 7.2
“Levothyroxine exposure was increased 33% (90% CI: 1.25 to 1.42) when administered with semaglutide tablets in a drug interaction study”
- 33.FDA label (DailyMed): Saxenda prescribing information, section 5.4
“The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogues) or insulin.”
- 34.FDA label (DailyMed): Saxenda prescribing information, section 6.1
“In this trial, among patients taking a sulfonylurea, hypoglycemia defined as a plasma glucose less than 54 mg/dL with or without symptoms occurred in 31 (28.2%) of 110 SAXENDA-treated patients and 7 (12.7%) of 55 placebo-treated patients.”
- 35.FDA label (DailyMed): Saxenda prescribing information, section 7.1
“SAXENDA causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications.”
- 36.FDA label (DailyMed): Saxenda prescribing information, section 1
“SAXENDA contains liraglutide. Coadministration with other liraglutide-containing products or with any other glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
Related pages
- Is Ozempic safe? What the GLP-1 labels and FDA say
- GLP-1s, pregnancy and breastfeeding: what each label says
- Who should not take Ozempic, Zepbound or another GLP-1?
- GLP-1 side effects: what the FDA labels report
- What is Zepbound? Uses, cost, doses and side effects
- What is Ozempic? Uses, doses, cost and how to take it
